Rein Therapeutics Q3 2025 Earnings Report

Rein Therapeutics EPS Results

• Actual EPS: -$0.21
• Consensus EPS: -$0.24
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: N/A

Rein Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Rein Therapeutics Announcement Details

• Quarter: Q3 2025
• Date: 11/14/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Rein Therapeutics (NASDAQ:RNTX) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer. In parallel, Rein is advancing additional IL-12-based programs such as RT-102, an IL-12-secreting natural killer (NK) cell therapy, and RT-103, an IL-12-secreting T-cell therapy, each aimed at leveraging distinct immune effector mechanisms.

Headquartered in Menlo Park, California, Rein Therapeutics trades on the Nasdaq under the symbol RNTX. The company’s clinical studies are primarily conducted at major cancer centers and academic institutions across North America, with plans to expand its geographic footprint as development progresses.

Rein collaborates with leading academic and research institutions to explore combination regimens and identify predictive biomarkers for patient selection. By refining its tunable IL-12 platform, the company seeks to address the unmet needs of patients whose tumors are refractory to existing immunotherapies, building a diversified pipeline of targeted cancer treatments.